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Summary: Cysteamine bitartrate capsules (Cystagon) have been approved by the 
US Food and Drug Administration for use in patients with nephropathic cystinosis. 
Plasma cysteamine concentrations were virtually identical at various times follow- 
ing ingestion of either cysteamine hydrochloride or Cystagon capsules in 24 normal 
control subjects. A transfer study was done with eight eystinosis patients who had 
been receiving either cysteamine hydrochloride or phosphocysteamine for many 
years. The plasma cysteamine concentration was significantly higher 2h after 
Cystagon and the leukocyte cystine content was significantly lower at all times after 
Cystagon compared to older forms of the drug. These differences are probably the 
result of greater patient compliance in taking the capsules compared to the older, 
liquid forms of the drug. A new method for following the course of renal glomerular 
deterioration in diseases such as cystinosis has been published recently. This method 
was used to re-analyse data on the efficacy of cysteamine treatment and to re-analyse 
new data on treating cystinosis patients with either of two doses of cysteamine 
(1.30g/m 2 per day and 1.95 g/m 2 per day). This new method agrees well with other 
methods and shows that both doses of drug are equally effective in maintaining 
glomerular function. 
This review of the treatment of cystinosis will be divided into three parts. First, we will 
describe our experience with cysteamine bitartrate capsules (Cystagon). This form of 
cysteamine was approved for treatment of nephropathic cystinosis by the US Food and 
Drug Administration on 15 August 1994. Next, we will discuss a new method to evaluate 
glomerular filtration rate over long periods in cystinosis patients. This method was 
reported in the August issue of Pediatric Nephrology (Manz and Gretz 1994). Finally, we 
will discuss practical aspects of treatment in this disease. 
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CYSTAGON (CYSTEAMINE BITARTRATE CAPSULES) 
The first form of cysteamine used to treat cystinosis was cysteamine hydrochloride 
(Thoene et al 1976). This is the least expensive form of the compound, but it has several 
disadvantages. In addition to being very foul smelling and tasting, it is extremely hygro- 
scopic. Thus, for accurate dispensing, the entire amount received must be rapidly weighed 
and dissolved in water. Fortunately, its acid pH keeps the compound in its reduced state. 
We have found it to be stable for many years at room temperature. In the United States it 
has been formulated to contain 50rag cysteamine base/ml. 
The next form of cysteamine used was the phosphorothioester of cysteamine, phospho- 
cysteamine (Thoene and Lemons 1980). In its pure form it is odourless and tasteless. How- 
ever, when manufactured in large enough quantity for clinical use it usually contains about 
0.5% cysteamine. This is enough to make this form almost as unpleasant as cysteamine 
hydrochloride. Phosphocysteamine has generally been dispensed in packets of 12.2g. 
When dissolved in 100 ml of water it contains 50 mg cysteamine base/ml. Before phospho- 
cysteamine was used in cystinosis patients it was tested and found to be equivalent to 
cysteamine hydrochloride (Smolin et al 1988). Phosphocysteamine is about three times as 
expensive as cysteamine hydrochloride and is difficult to manufacture in a reproducible way. 
When Mylin Pharmaceuticals agreed to sponsor cysteamine for New Drug Approval for 
cystinosis they decided to use the bitartrate salt of this compound. This is a stable solid 
that is water-soluble. They manufacture two sizes of capsules, 50mg and 150mg of 
cysteamine base. In order to convince ourselves and the Food and Drug Administration 
that these capsules were equivalent to both cysteamine and phosphocysteamine, the 
capsules were tested in both normal control individuals and cystinosis patients. 
Twenty-four healthy male control subjects were given either 1.05 g cysteamine hydro- 
chloride in solution or 1.05g cysteamine bitartate capsules (both expressed as g 
cysteamine base) in a random cross-over design with a 2-week 'wash-out' period between 
dose forms. The subjects fasted for 10h, had a standard breakfast at 07:30 and received the 
medication at 08:00. They had meals at noon and 18:00. Their plasma cysteamine 
concentrations following the drugs are shown in Figure 1. The mean peak cysteamine 
concentration is higher following the capsules and the curve is slightly shifted to the right. 
However, neither of these findings is statistically significant. 
A 'transfer study' was done with eight cystinosis patients who had each received either 
cysteamine hydrochloride or phosphocysteamine for many years. The average age of these 
patients was 10 years. Each patient was changed to a dose of their usual drug as close as 
possible to 1.3 g/m 2 per day with increments of 50mg/dose. (When administered in liquid 
form the dose could be adjusted by 0.1 ml (5 mg) increments. When administered as 
capsules the dose can only be changed by 50mg (one capsule) increments.) This allowed 
the patients to take the same dose of liquid medication that they would later take as 
capsules. The drug was given in four divided doses as close to every six hours as possible. 
On the fifth day the patients were admitted to a Clinical Research Center and continued on 
the same dose of cysteamine hydrochloride or phosphocysteamine. On both day 6 and day 
7 they received these medications at 08:00 following a breakfast that was standardized for 
each patient according to their customary meal. Blood was obtained at baseline, 1, 2 and 
6h for measurement of plasma cysteamine and leukocyte cystine. The patients were then 
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Figure 1 Plasma cysteamine concentration following either cysteamine hydrochloride solution 
(©) or cysteamine bitartrate capsules (O) in 24 normal control subjects. The values at 24h were zero 
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Figure 2 Plasma cysteamine concentration (mean _+ SEM) following either cysteamine 
hydrochloride or phosphocysteamine solution (©) or cysteamine bitartrate capsules (O) in eight 
cystinosis patients. A repeated measures analysis of variance was done with two repeated factors 
(form of drug and time) and comparisons of the dose forms at each time were done with Bonfen-oni 
adjustment of the p values. At 2h, p=0.006. The symbols for the capsule values are plotted slightly 
to the right for clarity. See text for details 
discharged from the hospital on the same dose of  cysteamine, but as cysteamine bitartrate 
capsules. After three weeks they were readmitted for repeat studies, while receiving the 
capsules. The results are shown in Figures 2 and 3. 
The plasma cysteamine concentration was significantly higher at 2h following the 
capsules as compared to the liquid forms of  this medication (Figure 2). The reason for this 
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Figure 3 Leukocyte cystine content (mean + SEM) following either cysteamine hydrochloride or 
phosphocysteamine solution (O) or cysteamine bitartrate capsules (0) in eight cystinosis patients, 
Statistical analysis was performed as in Figure 2. The repeated measures analysis of variance 
indicated that both the form of drug and time were significant factors. There was a differential 
response over time as indicated by the significant interaction (p=0.007). The significance at each 
time point was Oh, p =0.022; 1 h, p =0.067; 2h, p =0.014; 6h, p =0.026. See text for details 
is not clear. It may be related to the time required for the capsules to dissolve in the gut. 
However, this was not seen in the normal control subjects. Of greater surprise, the 
leukocyte cystine values were significantly lower following the capsules compared to the 
liquid forms of the drug (Figure 3). These values almost certainly reflect the amount of 
drug taken in the preceding several days. Thus, the differences are probably the result of 
greater patient compliance in taking the capsules compared to the liquid forms of the drug. 
The US Food and Drug Administration approved cysteamine bitartrate capsules 
(Cystagon) on 15 August 1994. In the United States it will be distributed by Chronimed 
Pharmacy, 13911 Ridgedale Drive, Minnetonka, MN 55305; phone (800) 444-5951; fax 
(612) 541-4969. 
EVALUATION OF GFR IN A HISTORICAL GROUP OF CYSTINOSIS 
PATIENTS 
Evaluating new therapies for cystinosis has been a humbling experience for clinical 
investigators. In the past, both a low-sulphur diet (Crawhall et al 1968; Bickel et al 1973) 
and D-penicillamine (Clayton and Patrick 1961; Hambraeus and Broberger 1967; Crawhall 
et al 1968) were reported to be effective therapies for this disease, but were later found to 
be ineffective. The difficulty is that most centres see very few of these patients and so 
studies usually involve several medical centres. In addition, glomerular filtration rate is 
very difficult to measure accurately in infants and small children. Some medical centres 
have a special interest in this measurement; others do not. It is often difficult to obtain 
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Figure 4 Standards for serum creatinine class values at each virtual age in patients with 
nephropathic cystinosis. These data are from 157 patients with both infantile and late-onset 
nephropathic cystinosis. 5th centile, O; 10th,[Z]; 25th, A; 50th, O 75th, n; 90th, A; 95th, O. See text 
for details. Redrawn from Manz and Gretz (1994) 
reproducible results both within and between centres. Previous clinical studies in 
cystinosis have relied only on measurements of  serum creatinine concentration and height 
by following the rise in serum creatinine concentration (Schneider et al 1979), calculated 
creatinine clearance (Gahl et al 1987), or predicted reciprocal serum creatinine at age 10 
years (Gahl et al 1990). A recent study was especially important because it measured 
creatinine clearance based on 24-h urine collections in 76 cystinosis patients followed over 
a 32-year period at a single clinical research centre (Markello et al 1993). 
A new method for following the course of  renal glomerular deterioration in diseases 
such as cystinosis has been published recently (Manz and Gretz 1994). These authors took 
data from 205 cystinosis patients who had been followed at seven European centres before 
the availability of  cysteamine (Gretz et al 1983). In brief, they first smoothed the 
longitudinal data of serum creatinine concentrations from each individual patient by the 
method of  running medians. They next defined 12 classes of  creatinine values 
(< 0.75 mg/dl = 0.5 mg/dl, 0 .75-1 .24mg/dl  = 1 mg/dl, and so on) and defined the term 
'virtual age' as the ' . . .  age at the last smoothed serum creatinine value observed in one 
defined creatinine class within an uninterrupted chronological file of  longitudinal 
smoothed serum creatinine values ... '. This then allowed them to perform statistical 
analysis on the virtual ages for each creatinine class. (See Manz and Gretz (1994) for 
details.) They had adequate data to do these analyses on 157 patients and plotted the 5th, 
10th, 25th, 50th, 75th, 90th and 95th centile for each creatinine class (Figure 4). They 
elected to include patients with late-onset cystinosis (Hooft et al 1971; Goldman et al 
1971; Langman et al 1985) in these data and thus the curves are shifted to the right 
compared to what they would have been if all patients had infantile-onset nephropathic 
cystinosis. We have prepared a °macro' in Panorama II for the Macintosh computer to 
evaluate data from our studies by this new method. (The macro is available without charge 
from J.A.S. You must have Panorama II in order to use it.) 
J. lnher. Metab. Dis. 18 ( 1 9 9 5 )  
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Figure 5 Virtual age (years) vs serum creatinine class (mg/dl) for patients who had never received 
cysteamine (Markello et al 1993). Virtual age was calculable for 26 of 27 such patients. Data were 
obtained from 351 visits. Mean +_ SD is plotted for each creatinine class unless there were fewer than 
three values in which case only the mean is shown 
The study from the NIH Clinical Center (Markello et al 1993) included 27 patients who 
had never received cysteamine. Virtual age data could be calculated on 26 of  theses 
patients as shown in Figure 5. The symbols in this figure show the m e a n + S D  at each 
creatinine class. The 'curve'  is very similar to the 50th centile in Figure 4. The NIH study 
also included 17 patients who were considered adequately treated with cysteamine. These 
adequately treated patients had started on cysteamine treatment before 2 years of  age and 
had leukocyte cystine levels that averaged less than 2 nmol half-cystine/mg protein 5 - 6  h 
after receiving cysteamine. By the method in Manz and Gretz (1994), the virtual age is that 
at which a patient's serum creatinine concentration passes to the next creatinine class. Only 
11 of the 17 adequately treated patients had creatinine values that ever increased enough 
to reach the next creatinine class. These data are shown in Figure 6. Figure 7 shows the 
data on all 17 patients, with the abscissa plotted as age rather than virtual age. These 
patients would appear to be at or above the 90th centile of retention of  glomerular function 
compared to the patients in Figure 4. 
The first study with cysteamine in a cystinosis patient determined that 60 mg cysteamine 
base per kg per day in four divided doses was a reasonable dose (Thoene et al 1976). This 
has continued to be the standard dose of  cysteamine for these patients. With this treatment, 
patients maintained their glomerular function much longer and attained greater weight 
than in the past. For some patients a dose of  60mg/kg became too great and we decided to 
base the dose on body surface area. We determined that a dose of 1.3 g/m 2 per day was 
equivalent to 60mg/kg per day for the average-sized 4-year-old cystinosis patient and 
made this the standard dose. To determine whether a higher dose would be more 
beneficial, we compared the standard dose to one 50% higher (1.95 g/m 2 per day) (Clark 
et al 1992). Some of the results of this study are shown below. 
Figures 8 and 9 show the creatinine data plotted according to Manz and Gretz (1994) 
for the patients receiving 1.3 g/m 2 per day. Virtual ages were calculable for only 48 of  the 
J. Inher. Metab. Dis. 1 8  ( 1 9 9 5 )  
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Figure 6 Virtual age (years) vs serum creatinine class (mg/dl) for patients who were considered to 
have received adequate treatment with cysteamine (Markello et al 1993). These patients began 
cystearnine before 2 years of age and maintained their mean leukocyte cystine value at below 2 nmol 
half-cystine/mg protein when blood was obtained 5 - 6 h  after medication. Virtual age was calculable 
for 11 of 17 such patients (7 at creatinine class 0.5 and 2 at creatinine class 1.0). Mean_+ SD is plotted 
for each creatinine class 
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Figure 7 Mean+SD is shown for the same patients as in Figure 6 except that the abscissa 
represents age (years) rather than virtual age. In this case data from 323 visits of all 17 patients are used 
patients (Figure 8). Thus, we also plotted the data using age on the abscissa (Figure 9). 
This provided data from 901 visits in 90 patients. The curves are very similar in the two 
figures and are comparable to about the 90th centile in Figure 4. Figures 10 and 11 show 
the data plotted for the patients who received 1.95 g/m 2 per day. Figure 10 plots the virtual 
age on the abscissa and includes only 28 patients. By using age on the abscissa, the data 
from all 75 patients can be used (Figure 11). The curves are very similar and virtually 
identical to each other and to those from the patients on the lower dose. These data 
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per day of cysteamine. Mean+SD is plotted for each creatinine class except for the value at 
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Figure 9 Data are shown for the same group of patients as in Figure 8 (dose of 1.3 g/m 2 per day of 
cysteamine) except that the abscissa represents age (years) rather than virtual age. Mean + SD is 
plotted for each creatinine class except for the value at creatinine class 8 mg/dl, which represents 
only one patient. In this figure data from 901 visits of  90 patients are used 
demonstrate the effectiveness of this drug in delaying glomerular deterioration in 
cystinosis patients. The reason more patients are shown for the lower than for the higher 
dose is that several patients could not tolerate the higher dose and exited the study. Most  
of  these patients then received the lower dose, but  were not included in the study. 
The 165 patients whose data were plotted in Figures 8 - 1 1  include some who started the 
drug after they were 2 years of  age and some who were not very compliant  in taking the 
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Figure 10 Virtual age (years) vs serum creatinine class (mg/dl) for patients who received 1.95 g/m 2 
per day of cysteamine. Mean+SD is plotted for each creatinine class except for the value at 
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Figure 11 Data are shown for the same group of patients as in Figure 10 (dose of 1.95 g/m 2 per day 
of cysteamine) except that the abscissa represents age (years) rather than virtual age. Mean+SD is 
plotted for each creatinine class except for the value at creatinine class 6 mg/dl, which represents 
only one patient. In this figure data from 763 visits of 75 patients are used 
drug. Still their average age of  glomerular deterioration places them at or above the 90th 
centile for untreated cystinosis patients. (Remember that the data in Figure 4 include 
patients with late-onset cystinosis whose glomerular deterioration occurs at an older age,) 
The results in Figures 8 -11  are important for another reason. When the cysteamine 
hydrochloride and phosphocysteamine were given in solution (50mg/ml), it was possible 
to change a patient's dose by increments of  5 mg (0.1 ml). The smallest capsule of 
Cystagon is 50rag. Thus, a patient's dose can be changed only by increments of 50rag 
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Table 1 Approximate recommended dose of eysteamine for patients with 
nephropathie eystinosis 
lb kg mg per 6h 
< 10 < 4.5 100 
10-20 4.6-9.1 150 
20-30 9.2-13.6 200 
30-40 13.7-18.2 250 
40-50 18.3-22.7 300 
50-70 22.8-31.8 350 
70-  90 31.9 - 40.9 400 
90 - 110 41.0-50.0 450 
> 110 >50.1 500 
The dose should be checked each 3-4 months by obtaining blood 5-6h after receiving 
cysteamine and preparing leukocytes for cystine measurement. The optimum value is 
less than 1.0nmol half-cystine per mg protein 
without opening capsules and dissolving them in liquid. The fact that the dose of  
cysteamine can range from 1.3 to 1.95 g / m  z per day and still be effective in delaying 
glomerular deterioration is very reassuring. 
P R A C T I C A L  S U G G E S T I O N S  
Participants at the 32rid Annual Symposium of the SSIEM in Edinburgh seemed especially 
interested in the following practical suggestions on the treatment of  cystinosis with 
cysteamine. 
(1) Start cysteamine therapy at as early an age as possible. It is now essential to deter- 
mine whether patients with the Fanconi syndrome have cystinosis as an urgent 
diagnosis, so that cysteamine treatment can be started at once. 
(2) Start new patients at a low dose and take 4 - 6  weeks to reach the 'full dose'. 
(3) A good starting 'full dose'  is 1.3 g/m 2 per day. Table 1 approximates this dose for 
most patients. 
(4) Have the patient take this drug as close to every 6h as possible. The drug is best 
tolerated if taken just after or with food. 
(5) To ensure appropriate dosage and patient compliance, follow the patient's leukocyte 
cystine content every 3 - 4  months. Obtain the blood 5 - 6  h after the medication is 
given for this measurement. 
(6) Aim for a dose that keeps the leukocyte cystine below 1.0nmol half-cystine/mg 
protein. A value less than 2 is beneficial, but the patients who do best are those who are 
able to keep their level below 1 when the blood is obtained at the appropriate time. 
Of course, there are several aspects of  cystinosis treatment that are not related to 
cysteamine. There are many recent reviews on this topic (Schneider 1994; Gahl et al 1995). 
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